

## Response to questions – Senator Green

- **Program 4.3** - Pharmaceutical Benefits Advisory Committee recommendations - an updated list of outstanding PBAC recommendations since 2013 (noting that the 'Medicine Status Website' does not include any recommendations made before July 2019).

Please see **Attachment X**

## **Medicines recommended by the PBAC which are being progressed by the Department of Health**

The Medicine Status website (MSW) now contains all PBAC recommendations from July 2019 onwards. The Department of Health is negotiating with sponsors who have received a positive recommendation to reach an agreement that is consistent with the PBAC recommendation. This website is updated regularly so that the public can monitor the listing steps. The MSW can be accessed at [www.pbs.gov.au/medicinesstatus/home.html](http://www.pbs.gov.au/medicinesstatus/home.html)

The table below outlines medicines recommended by the PBAC prior to July 2019 PBAC meeting, and therefore not listed on the MSW, and where the sponsor company has indicated that they wish to proceed to a listing but that listing is not finalised.

**Table 1:** current as at 18 March 2021

<b>PBAC Meeting March 2019</b>		
ALIROCUMAB Praluent®	Hypercholesterolaemia	Under negotiation
BUDESONIDE Entocort®	Mild to moderate Crohn disease	No listing proposal received from sponsor that is consistent with PBAC recommendation
CERTOLIZUMAB PEGOL Cimzia®	Severe chronic plaque psoriasis	No listing proposal received from sponsor that is consistent with PBAC recommendation
<b>PBAC Meeting March 2018</b>		
RAMUCIRUMAB (Cyramza®)	Advanced gastric or gastro-oesophageal junction adenocarcinomas	No listing proposal received from sponsor that is consistent with PBAC recommendation
RANOLAZINE (Ranexa®)	Stable angina pectoris	No listing proposal received from sponsor that is consistent with PBAC recommendation
<b>PBAC Meeting November 2017</b>		
SEVELAMER Renvela®	Hyperphosphataemia in patients with chronic kidney disease	No listing proposal received from sponsor
<b>PBAC Meeting March 2017</b>		
TENOFOVIR ALAFENAMIDE Vemlidy®	Chronic hepatitis B	No listing proposal received from sponsor that is consistent with PBAC recommendation

**Medicines recommended by the PBAC prior to July 2019, where the sponsor company has advised that it will not be progressing the recommendation and therefore it is not possible for the Government to list on the PBS**

**Table 2:** Current as of 18 March 2021

<b>MEDICINE</b>	<b>INDICATION</b>
<b>PBAC meeting March 2019</b>	
BUDESONIDE Budenofalk®	Crohn disease
<b>PBAC Meeting November 2018</b>	
SARILUMAB Injection 200mg in 1.14mL	Rheumatoid arthritis
<b>PBAC Meeting July 2018</b>	
ARIPIRAZOLE Abilify Maintena®	Schizophrenia
MENINGOCOCCAL POLYSACCHARIDE SERO (GROUPS A, C, W-135 AND Y) OLIGOSACCHARIDE CONJUGATE VACCINE	Meningococcal disease
<b>PBAC meeting March 2018</b>	
CETUXIMAB Erbitux®	squamous cell carcinoma of the head and neck
TENECTEPLASE Metalyse®	Acute myocardial infarction
<b>PBAC meeting November 2017</b>	
CANAKINUMAB Ilaris®	Cryopyrin associated periodic syndromes (CAPS)
RADIUM (223Ra) Xofigo®	Metastatic castrate resistant prostate cancer (mCRPC)
<b>PBAC meeting July 2017</b>	
ADALIMUMAB Humira®	Multiple indications
<b>PBAC meeting March 2017</b>	
RITUXIMAB MabThera SC®	Chronic lymphocytic leukaemia
<b>PBAC meeting November 2016</b>	
PARITAPREVIR WITH RITONAVIR WITH OMBITASVIR Technivie®	Hepatitis C
<b>PBAC meeting July 2016</b>	
ADRENALINE Adrenaline Auto Inject Sun-JV®	Anaphylaxis
ALENDRONIC ACID Binosto®	Osteoporosis
DENOSUMAB Xgeva®	Hypercalcaemia of malignancy
<b>PBAC meeting March 2016</b>	
TRIGLYCERIDES MEDIUM CHAIN Peptamen Junior Liquid® Peptamen Junior Advance®	Multiple indications